ReviewNutrients2021
A Link between Chronic Kidney Disease and Gut Microbiota in Immunological and Nutritional Aspects.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Effects of probiotic supplementation on diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials.Frontiers in microbiology · 2026Pooled it
- Pooled it
- Observational
- Nutritional and Metabolic Interventions to Prevent and Treat Protein-Energy Wasting in Nondialysis CKD-Narrative Review.Nutrients · 2026Review
- Blood Metabolites Mediate the Effects of Gut Microbiota on Diabetic Nephropathy: A Mendelian Randomization Study.International journal of endocrinology · 2026Article
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Targeted modulation of intestinal barrier and mucosal immune-related microbiota attenuates IgA nephropathy progression.Gut microbes · 2025Article
- The association between dietary live microbe intake and risk of chronic kidney disease among US adults: a cross-sectional survey from NHANES (2001-2018).Renal failure · 2025Article
- Metagenomic profiling of gut microbime: associating their role with the advancement of diabetic nephropathy.Antonie van Leeuwenhoek · 2025Review
- Gut microbiota pattern in children and adolescents with newly diagnosed immune thrombocytopenia.BMC pediatrics · 2025Article
- Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.International journal of molecular sciences · 2025Review
- Early detection of feline chronic kidney disease via 3-hydroxykynurenine and machine learning.Scientific reports · 2025Article
- Article
- Innovative Treatments to Counteract Endothelial Dysfunction in Chronic Kidney Disease Patients.Biomedicines · 2024Review
- Chronic Kidney Disease Diets for Kidney Failure Prevention: Insights from the IL-11 Paradigm.Nutrients · 2024Review
- Untargeted metabolomic profiling of serum from client-owned cats with early and late-stage chronic kidney disease.Scientific reports · 2024Article
- New insights into the intestinal barrier through "gut-organ" axes and a glimpse of the microgravity's effects on intestinal barrier.Frontiers in physiology · 2024Review
- Immune Microenvironment Alterations and Identification of Key Diagnostic Biomarkers in Chronic Kidney Disease Using Integrated Bioinformatics and Machine Learning.Pharmacogenomics and personalized medicine · 2024Article
- Shenshuaikang enema restores the intestinal barrier and microbiota-gut-kidney axis balance to alleviate chronic kidney disease via NF-κB pathway.Frontiers in pharmacology · 2024Article
- Clinical Perspectives of Gut Microbiota in Patients with Chronic Kidney Disease and End-Stage Kidney Disease: Where Do We Stand?Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is generally progressive and irreversible, structural or functional renal impairment for 3 or more months affecting multiple metabolic pathways. Recently, the composition, dynamics, and stability of a patient's microbiota has been noted to play a significant role during disease onset or progression. Increasing urea concentration during CKD can lead to an acceleration of the process of kidney injury leading to alterations in the intestinal microbiota that can increase the production of gut-derived toxins and alter the intestinal epithelial barrier. A detailed analysis of the relationship between the role of intestinal microbiota and the development of inflammation within the symbiotic and dysbiotic intestinal microbiota showed significant changes in kidney dysfunction. Several recent studies have determined that dietary factors can significantly influence the activation of immune cells and their mediators. Moreover, dietary changes can profoundly affect the balance of gut microbiota. The aim of this review is to present the importance and factors influencing the differentiation of the human microbiota in the progression of kidney diseases, such as CKD, IgA nephropathy, idiopatic nephropathy, and diabetic kidney disease, with particular emphasis on the role of the immune system. Moreover, the effects of nutrients, bioactive compounds on the immune system in development of chronic kidney disease were reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.